# Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

> **NCT05577988** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 2468 (estimated)

## Conditions studied

- MYOCARDIAL INFARCTION

## Interventions

- **OTHER:** single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

## Key facts

- **NCT ID:** NCT05577988
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-18
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 2468 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577988, "Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05577988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*